GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    Springer Science and Business Media LLC ; 2017
    In:  Journal of Molecular Medicine Vol. 95, No. 4 ( 2017-4), p. 405-416
    In: Journal of Molecular Medicine, Springer Science and Business Media LLC, Vol. 95, No. 4 ( 2017-4), p. 405-416
    Type of Medium: Online Resource
    ISSN: 0946-2716 , 1432-1440
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2017
    detail.hit.zdb_id: 1462132-0
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: ESMO Open, Elsevier BV, Vol. 4, No. 6 ( 2019), p. e000575-
    Type of Medium: Online Resource
    ISSN: 2059-7029
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2019
    detail.hit.zdb_id: 2844985-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Journal of Experimental & Clinical Cancer Research, Springer Science and Business Media LLC, Vol. 38, No. 1 ( 2019-12)
    Abstract: We investigated the role of PD-L1 in the metabolic reprogramming of non-small cell lung cancer (NSCLC). Methods Changes in glycolysis-related molecules and glycolytic activity were evaluated in PD-L1 low and PD-L1 high NSCLC cells after transfection or knockdown of PD-L1 , respectively. Jurkat T-cell activation was assessed after co-culture with NSCLC cells. The association between PD-L1 and immune response-related molecules or glycolysis were analyzed in patients with NSCLC and The Cancer Genome Atlas (TCGA). Results Transfecting PD-L1 in PD-L1 low cells enhanced hexokinase-2 (HK2) expression, lactate production, and extracellular acidification rates, but minimally altered GLUT1 and PKM2 expression and oxygen consumption rates. By contrast, knocking-down PD-L1 in PD-L1 high cells decreased HK2 expression and glycolysis by suppressing PI3K/Akt and Erk pathways. Interferon-γ (IFNγ) secretion and activation marker expression was decreased in stimulated Jurkat T-cells when co-cultured with HK2-overexpressing vector-transfected tumor cells rather than empty vector-transfected tumor cells. Immunohistochemistry revealed that PD-L1 expression was positively correlated with HK2 expression in NSCLC ( p   〈  0.001). In TCGA, HK2 exhibited a positive linear association with CD274 (PD-L1) expression ( p   〈  0.001) but an inverse correlation with the expression of CD4 , CD8A , and T-cell effector function-related genes in the CD274 high rather than CD274 low group. Consistently, there were fewer CD8 + T-cells in PD-L1 positive /HK2 high tumors compared to PD-L1 positive /HK2 low tumors in squamous cell carcinoma. Conclusions PD-L1 enhances glycolysis in NSCLC by upregulating HK2, which might dampen anti-tumor immunity. PD-L1 may contribute to NSCLC oncogenesis by inducing metabolic reprogramming and immune checkpoint.
    Type of Medium: Online Resource
    ISSN: 1756-9966
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2019
    detail.hit.zdb_id: 2430698-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Cancer Research and Treatment, Korean Cancer Association, Vol. 55, No. 2 ( 2023-04-15), p. 523-530
    Abstract: Purpose This single-arm phase II trial investigate the efficacy and safety of S-1 plus oxaliplatin (SOX) in patients with metastatic breast cancer.Materials and Methods Patients with metastatic breast cancer previously treated with anthracyclines and taxanes were enrolled. Patients received S-1 (40-60 mg depending on patient’s body surface area, twice a day, day 1-14) and oxaliplatin (130 mg/m2, day 1) in 3 weeks cycle until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumor 1.1. Secondary endpoints included time-to-progression (TTP), duration-of-response (DoR), overall survival (OS), and adverse events.Results A total of 87 patients were enrolled from 11 institutions in Korea. Hormone receptor was positive in 54 (62.1%) patients and six (6.9%) had human epidermal growth factor receptor 2–positive disease. Forty-eight patients (85.1%) had visceral metastasis and 74 (55.2%) had more than three sites of metastases. The ORR of SOX regimen was 38.5% (95% confidence interval [CI], 26.9 to 50.0) with a median TTP of 6.0 months (95% CI, 5.1 to 6.9). Median DoR and OS were 10.3 months (95% CI, 5.5 to 15.1) and 19.4 (95% CI, not estimated) months, respectively. Grade 3 or 4 neutropenia was reported in 28 patients (32.1%) and thrombocytopenia was observed in 23 patients (26.6%).Conclusion This phase II study showed that SOX regimen is a reasonable option in metastatic breast cancer previously treated with anthracyclines and taxanes.
    Type of Medium: Online Resource
    ISSN: 1598-2998 , 2005-9256
    Language: English
    Publisher: Korean Cancer Association
    Publication Date: 2023
    detail.hit.zdb_id: 2514151-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Metabolism, Elsevier BV, Vol. 66 ( 2017-01), p. 32-44
    Type of Medium: Online Resource
    ISSN: 0026-0495
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2017
    detail.hit.zdb_id: 2049062-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 41, No. 16_suppl ( 2023-06-01), p. e20520-e20520
    Abstract: e20520 Background: Recent data suggested immune infiltrates in TLS around tumor bed may be a favorable predictive factor for immunotherapy in various cancers. TLS have been suggested to be correlated with inflamed immune phenotype and relevant inflammatory gene signatures of adaptive immunity. To analyze this relationship, here, we developed an AI model to assess TLS objectively in H & E WSI, and assessed its correlation with immune phenotype and immunologic signatures. Methods: H & E images, relevant gene expression profiles and clinical data from The Cancer Genome Atlas (TCGA) lung cancer dataset (LUAD and LUSC, N = 913) were used for the analysis. Lunit SCOPE TLS, an AI-powered H & E WSI analyzer, was developed with 3.59 x 10 9 μm 2 annotated area and 1,439 H & E stained WSI of 18 cancer types to segment TLS within tumor microenvironment (TME). Based on spatial tumor-infiltrating lymphocyte (TIL) density, IPs were classified into inflamed IP (IIP) as high intratumoral TIL (iTIL), immune-excluded IP (IEP) as low iTIL and high sTIL, and immune-desert IP (IDP) as low TIL overall. The infiltration of immune cells, the activity of related pathways and biological processes, and the signature scores of interest gene sets were analyzed by using the CIBERSORT, DESeq2 and GSEA tools. Results: Of 913 samples, 69.7% (636/913) contain TLS. The median value of the proportion of TLS area within TME was 0.12%, which was applied for the cut point of TLS-high vs -low group. The proportion of TLS-high was not significantly different according to EGFR mutation (mutation vs wild type: 45.5% vs 50.2%), KRAS mutation (49.3% vs 50%), but numerically decreased in the merging set of other driver mutations including ALK, ROS1, RET, MET, NTRK1-3 (36% vs 50.3%, p = 0.223). Interestingly, TLS-high proportion was significantly different according to immune phenotype, as TLS were present in 57.6% of IIP (186/323), 49.8% of IEP (241/484), and 28.3% of IDP (30/106, p 〈 0.001). TLS-high group was positively correlated with memory B cells (fold change [fc] 1.93, p 〈 0.001), CD8+ T cells (fc 1.20, p 〈 0.001), and M1 Macrophages (fc 1.17, p 〈 0.001), and negatively correlated with neutrophils (fc 0.59, p 〈 0.001) and M2 macrophages (fc 0.91, p = 0.006). This result was additionally supported by GSEA analysis of GO:BP or Hallmark gene sets which showed TLS-high was associated with B cell receptor signaling pathway (normalized enrichment score [NES] 3.16, p = 0.001), immunoglobulin production (NES 3.07, p = 0.002), and interferon-gamma response (NES 2.20, p = 0.002). Epithelial-mesenchymal transition was negatively associated with TLS-high (NES -1.54, p 〈 0.001). Conclusions: TLS is associated with inflamed immune phenotype and infiltration of memory B cells as well as CD8+ T cells in non-small cell lung cancer.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2023
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 41, No. 16_suppl ( 2023-06-01), p. 6100-6100
    Abstract: 6100 Background: Different biomarkers have been discovered to predict response to immunotherapy but the variability of response exists. TILs are a potential biomarker as infiltration of CD8+ T cells in the tumor microenvironment(TME) was related to treatment response to PD-1 blockade. Advanced well-differentiated papillary thyroid cancer(PTC) has limited standard-of-care treatment options and can exhibit a poor prognosis when exhausted. Our study aimed to classify the TME of PTC according to TILs. Methods: Using the TCGA PTC data, samples were classified into three immune phenotypes (immune-’desert’, immune-’excluded’, and ‘inflamed’) based on peri-tumor lymphocyte density from analysis of H & E slides using an AI model(Lunit SCOPE). Immune and stromal cell infiltration was inferred using xCell. Cytolytic scores(CYT) and thyroid differentiation scores(TDS) were calculated using mRNA expression. Results: Total of 383 samples were included. Immune phenotype analysis showed 183(47.7%) ‘desert’, 133(34.7%) ‘excluded’, and 67(17.4%) ‘inflamed’. Median age at diagnosis was the lowest in ‘inflamed’(inflamed 41.5 vs excluded 47 vs desert 50, p = 002). TNM stages were as follows in the order of stages 1 to 4: inflamed 49/4/8/3, excluded 64/13/32/16, and desert 86/28/40/19. BRAF V600E mutation was most prevalent in ‘excluded’(97/133, 72%), followed by ‘inflamed’(32/67, 47.7%) and ‘desert’(51/183, 27.8%). CYT was the highest in ‘inflamed’(median: inflamed 186 vs excluded 53 vs desert 39, p 〈 0.001). TDS was the highest in ‘desert’(median: inflamed -0.3 vs excluded -0.69 vs desert 0.73, p 〈 0.001). The 6 cell types with the most statistically significant difference in infiltration were activated dendritic cells(aDCs), DCs, B cells, epithelial cells(EpCs), CD8+ central memory T cells, and CD4+ memory T cells. The ‘inflamed’ showed the highest median value for all of these cells except EpCs. The cells with the highest median value in ‘excluded’ included EpCs, sebocytes, and immature DCs. The cells with the highest median value in ‘desert’ were lymphatic endothelial cells(ECs), ECs, and osteoblasts. Three immune phenotypes were associated with differential outcomes in disease-free survival(log-rank for trend, p-value = 0.01). There was no difference in overall survival. Conclusions: Our results suggest that 15% of PTC can have immune features which were related to a higher rate of response to immunotherapy across different tumor types. A previous study showed that PTC with a low TDS or BRAF V600E mutation is related to increased immune response indices. In our study, TDS or BRAF V600E mutation status could not distinguish the ‘inflamed’ from other phenotypes. This suggests that immune phenotype classification through TILs can provide distinct information about the TME of PTC.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2023
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: PLOS ONE, Public Library of Science (PLoS), Vol. 18, No. 2 ( 2023-2-9), p. e0281422-
    Abstract: PubMed is the most extensively used database and search engine in the biomedical and healthcare fields. However, users could experience several difficulties in acquiring their target papers facing massive numbers of search results, especially in their unfamiliar fields. Therefore, we developed a novel user interface for PubMed and conducted three steps of study: step A, a preliminary user survey with 76 medical experts regarding the current usability for the biomedical literature search task at PubMed; step B is implementing EEEvis, a novel interactive visual analytic system for the search task; step C, a randomized user study comparing PubMed and EEEvis. First, we conducted a Google survey of 76 medical experts regarding the unmet needs of PubMed and the user requirements for a novel search interface. According to the data of preliminary Google survey, we implemented a novel interactive visual analytic system for biomedical literature search. This EEEvis provides enhanced literature data analysis functions including (1) an overview of the bibliographic features including publication date, citation count, and impact factors, (2) an overview of the co-authorship network, and (3) interactive sorting, filtering, and highlighting. In the randomized user study of 24 medical experts, the search speed of EEEvis was not inferior to PubMed in the time to reach the first article (median difference 3 sec, 95% CI -2.1 to 8.5, P = 0.535) nor in the search completion time (median difference 8 sec, 95% CI -4.7 to 19.1, P = 0.771). However, 22 participants (91.7%) responded that they are willing to use EEEvis as their first choice for a biomedical literature search task, and 21 participants (87.5%) answered the bibliographic sorting and filtering functionalities of EEEvis as a major advantage. EEEvis could be a supplementary interface for PubMed that can enhance the user experience in the search for biomedical literature.
    Type of Medium: Online Resource
    ISSN: 1932-6203
    Language: English
    Publisher: Public Library of Science (PLoS)
    Publication Date: 2023
    detail.hit.zdb_id: 2267670-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2021
    In:  Cancer Research Vol. 81, No. 13_Supplement ( 2021-07-01), p. 248-248
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 81, No. 13_Supplement ( 2021-07-01), p. 248-248
    Abstract: PubMed is the most widely used database and search-engine in biomedical and healthcare field. It has evolved more powerfully using Best Match algorithm. However, users still have several difficulties to ‘catch' their target papers in limited time, which fundamentally originates from the conventional two-dimensional ‘top-down' display method of search results. We conducted a survey for 76 medical experts (including oncologists, surgeons, gastroenterologists, psychiatrists, et al) about their behaviors and difficulties in using PubMed. The most common ‘unmet needs' of users were (1) the rank of citation counts or impact factors, (2) more three-dimensional and interactive display of search results, and (3) author rank and network. Reflecting the results above, we developed a novel PubMed visualizing program, EEEvis version 1.0 (medical and healthcare evidence visualizer), and launched it on www.EEEvis.com. The basic operating principle of EEEvis version 1.0 is to visualize the metadata of PubMed and PubTator (a web-based text mining-tool) using (1) advanced filter tools, (2) a scatter & box plot using citation counts over years, (3) an author map reflecting the ranks and networks, and (4) a reinforced search list (Table 1). All the data crawling is based on the API (application programming interface) of PubMed and PubTator. To computing and visualizing the crawled metadata, we constructed two servers; a hidden station server and an open UI (user interface) server. In the interim result of our ongoing pilot study in searching oncology-related literatures, the two quantitative factors including (1) time to ‘catch' the target paper and (2) success rate finding the required paper showed significant improvement. Other qualitative factors including (3) user convenience, (4) interactivity, and (5) willingness to use EEEvis next time showed good results. Now we are developing EEEvis version 2.0 using text-mining technology and applying multiple patents for this program. Comparison between EEEvis and PubMedProgramsEEEvisPubMedFilter sectionBy article typeYesYesBy publication yearYesYesBy citation count of paperYesNoBy impact factor of journalYesNoInteraction section using Brushing & Linking techniqueScatter plot of citation counts by yearYesNo(with box plot of citation counts by year)YesNoMap of author networkYesNoList sectionSort by best matchYesYesSort by most recentYesYesSort by citation countYesNoSort by author or journalNoYesCitation count of each paperYesNoImpact factor of each journalYesNoPubTator informationYesNoData crawlingHow to crawl results from Pubmed serverIndirect using APIDirectLimit of result numbers10,000 (best matched)NoneUser experience in searching cancer-related keywords in pilot study (ongoing)Time to display results after entering keywordsNot inferiorPromptTime from visualizing results to finding the required paperSuperior(= faster)InferiorSuccess rate of finding the required paper after visualizing the resultsSuperiorInferior Citation Format: Jong-chan Lee, Brian J. Lee, Hyunjoo Song, Changhee Park, Chan-Young Ock, Yuna Youn, Hyojae Sung, Sungjin Woo, Jaihwan Kim, Jin-Hyeok Hwang. A novel PubMed visualizer using human-computer interaction technology: EEEvis.com [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 248.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2021
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 39, No. 15_suppl ( 2021-05-20), p. e14552-e14552
    Abstract: e14552 Background: YBL-006 is an anti-programmed death-1 (PD-1) antibody with a higher affinity compared to that of other PD-1 antibodies, which showed a favorable safety profile in animal models. We designed the first-in-human phase I trial of YBL-006 to assess its safety and efficacy with exploratory biomarker analysis in patients with advanced solid tumors refractory to standard of treatment. Methods: A modified “3+3” design, with the first patient dosed at 0.5 mpk, was followed by conventional dose escalation of 2, 5, and 10 mpk IV. Pharmacokinetics (PK) and pharmacodynamics, including PD-1 receptor occupancy (RO) and serum levels of interferon-gamma (IFN-γ), were assessed. Adverse events (AEs) were graded using the CTCAE v4.03. Tumor response was assessed using the RECIST v1.1 every 8 weeks. For exploratory analysis, tumor mutational burden (TMB) and AI-powered spatial analysis of tumor-infiltrating lymphocyte (TIL) of tumor tissues collected before YBL-006 treatment were performed. The cut-off date for analysis was February 12, 2021. Results: A total of 8 patients enrolled in the 0.5, 2, and 5 mpk cohorts received at least one dose of YBL-006 and median exposure was 15 weeks (ranged 4-26). No dose limiting toxicity occurred and the maximum tolerated dose was not reached until progressing to the 5 mpk. The common treatment-related AEs were G1 fatigue (25%), and G1 hypothyroidism (12.5%). We also observed 1 case of G2 cytokine release syndrome during cycle 1 in 2 mpk which was managed with supportive care alone. No treatment-related deaths have occurred to date. YBL-006 showed a linear PK prolife and both PD-1 RO and serum IFN-γ increased by 〉 2 times 8 h after the first dose. Tumor evaluation data were available for 7 patients, which showed 1 confirmed complete response (CR, penile squamous cell carcinoma, 2 mpk) and 1 confirmed partial response (PR, anal squamous cell carcinoma, 2 mpk) with durable responses lasting more than 19+ and 10+ weeks respectively, 2 stable disease (SD) and 3 progressive disease (PD). Four tumor samples were available for biomarker analysis. TMBs of patients with CR (8.3/Mb) or PR (9.3/Mb) were higher than those in 2 patients with PD (5.5 and 1.7/Mb). AI-powered spatial analysis of TIL showed that intratumoral TIL density was increased in patients who achieved CR and PR (66.1% and 95.8%, respectively) compared to those in patients who exhibited PD (25.1% and 16.5%, respectively). Conclusions: Interim analysis of phase I study showed that YBL-006 is well tolerated and preliminary biomarker analysis showed that the TMB, and intratumoral TIL infiltration are potentially related to the response to YBL-006. Clinical trial information: NCT04450901.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2021
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...